Natural History of Hepatitis C in Patients With Normal Liver Tests
NCT ID: NCT00187473
Last Updated: 2024-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
92 participants
OBSERVATIONAL
2000-06-30
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anticipated and Perceived Benefits Following Hepatitis C Treatment
NCT03000023
Transforming the Cascade Of Hepatitis C Care
NCT03226509
Identifying the Gaps in the Diagnosis and Management of Hepatitis C
NCT00976781
HCV Virions Bound Proteins
NCT02795403
A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C
NCT01705717
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
liver biopsy
Liver biopsy every 5 years
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* able to give consent
Exclusion Criteria
* any prior antiviral or immunosuppressive therapy
* other liver disease besides hepatitis C
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, San Francisco
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mandana Khalili, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H10102-17633
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.